Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt No Debt
LMAT's Cash to Debt is ranked higher than
100% of the 292 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.03 vs. LMAT: No Debt )
LMAT' s 10-Year Cash to Debt Range
Min: 0.43   Max: No Debt
Current: No Debt

Equity to Asset 0.84
LMAT's Equity to Asset is ranked higher than
91% of the 290 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.58 vs. LMAT: 0.84 )
LMAT' s 10-Year Equity to Asset Range
Min: 0.14   Max: 0.89
Current: 0.84

0.14
0.89
Interest Coverage 1268.00
LMAT's Interest Coverage is ranked higher than
81% of the 176 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 23.54 vs. LMAT: 1268.00 )
LMAT' s 10-Year Interest Coverage Range
Min: 2.32   Max: 9999.99
Current: 1268

2.32
9999.99
F-Score: 6
Z-Score: 8.34
M-Score: -2.48
WACC vs ROIC
6.14%
8.64%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) 8.92
LMAT's Operating margin (%) is ranked higher than
75% of the 291 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9.92 vs. LMAT: 8.92 )
LMAT' s 10-Year Operating margin (%) Range
Min: -10.33   Max: 8.92
Current: 8.92

-10.33
8.92
Net-margin (%) 5.51
LMAT's Net-margin (%) is ranked higher than
75% of the 291 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.36 vs. LMAT: 5.51 )
LMAT' s 10-Year Net-margin (%) Range
Min: -7.08   Max: 10.73
Current: 5.51

-7.08
10.73
ROE (%) 6.20
LMAT's ROE (%) is ranked higher than
72% of the 282 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 8.53 vs. LMAT: 6.20 )
LMAT' s 10-Year ROE (%) Range
Min: -7.03   Max: 12.52
Current: 6.2

-7.03
12.52
ROA (%) 5.09
LMAT's ROA (%) is ranked higher than
77% of the 294 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.87 vs. LMAT: 5.09 )
LMAT' s 10-Year ROA (%) Range
Min: -5.75   Max: 10.01
Current: 5.09

-5.75
10.01
ROC (Joel Greenblatt) (%) 25.18
LMAT's ROC (Joel Greenblatt) (%) is ranked higher than
81% of the 291 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 20.54 vs. LMAT: 25.18 )
LMAT' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -38.66   Max: 51.47
Current: 25.18

-38.66
51.47
Revenue Growth (3Y)(%) 5.00
LMAT's Revenue Growth (3Y)(%) is ranked higher than
73% of the 259 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.70 vs. LMAT: 5.00 )
LMAT' s 10-Year Revenue Growth (3Y)(%) Range
Min: -4.9   Max: 21.4
Current: 5

-4.9
21.4
EBITDA Growth (3Y)(%) 16.60
LMAT's EBITDA Growth (3Y)(%) is ranked higher than
85% of the 225 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.00 vs. LMAT: 16.60 )
LMAT' s 10-Year EBITDA Growth (3Y)(%) Range
Min: 0   Max: 27.9
Current: 16.6

0
27.9
EPS Growth (3Y)(%) 20.90
LMAT's EPS Growth (3Y)(%) is ranked higher than
87% of the 221 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 8.10 vs. LMAT: 20.90 )
LMAT' s 10-Year EPS Growth (3Y)(%) Range
Min: -45   Max: 44.2
Current: 20.9

-45
44.2
» LMAT's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2014

LMAT Guru Trades in Q1 2014

Jim Simons 13,278 sh (New)
» More
Q2 2014

LMAT Guru Trades in Q2 2014

Jim Simons 20,262 sh (+52.60%)
» More
Q3 2014

LMAT Guru Trades in Q3 2014

Jim Simons 27,400 sh (+35.23%)
» More
Q4 2014

LMAT Guru Trades in Q4 2014

Jim Simons 43,063 sh (+57.16%)
» More
» Details

Insider Trades

Latest Guru Trades with LMAT

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Guru Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 36.30
LMAT's P/E(ttm) is ranked higher than
79% of the 309 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 45.70 vs. LMAT: 36.30 )
LMAT' s 10-Year P/E(ttm) Range
Min: 15.99   Max: 125
Current: 36.3

15.99
125
Forward P/E 24.81
LMAT's Forward P/E is ranked higher than
81% of the 309 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 33.56 vs. LMAT: 24.81 )
N/A
PE(NRI) 36.20
LMAT's PE(NRI) is ranked higher than
78% of the 309 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 45.40 vs. LMAT: 36.20 )
LMAT' s 10-Year PE(NRI) Range
Min: 15.93   Max: 125
Current: 36.2

15.93
125
P/B 2.10
LMAT's P/B is ranked higher than
80% of the 309 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.70 vs. LMAT: 2.10 )
LMAT' s 10-Year P/B Range
Min: 0.67   Max: 2.41
Current: 2.1

0.67
2.41
P/S 1.98
LMAT's P/S is ranked higher than
79% of the 309 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.99 vs. LMAT: 1.98 )
LMAT' s 10-Year P/S Range
Min: 0.63   Max: 2.98
Current: 1.98

0.63
2.98
PFCF 36.00
LMAT's PFCF is ranked higher than
81% of the 309 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 61.06 vs. LMAT: 36.00 )
LMAT' s 10-Year PFCF Range
Min: 9.1   Max: 116.17
Current: 36

9.1
116.17
POCF 27.77
LMAT's POCF is ranked higher than
73% of the 309 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 24.84 vs. LMAT: 27.77 )
LMAT' s 10-Year POCF Range
Min: 8.42   Max: 76.33
Current: 27.77

8.42
76.33
EV-to-EBIT 20.05
LMAT's EV-to-EBIT is ranked higher than
85% of the 309 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 30.15 vs. LMAT: 20.05 )
LMAT' s 10-Year EV-to-EBIT Range
Min: -831.4   Max: 61.8
Current: 20.05

-831.4
61.8
PEG 2.13
LMAT's PEG is ranked higher than
93% of the 309 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.00 vs. LMAT: 2.13 )
LMAT' s 10-Year PEG Range
Min: 2.11   Max: 4.7
Current: 2.13

2.11
4.7
Shiller P/E 39.10
LMAT's Shiller P/E is ranked higher than
84% of the 309 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 168.61 vs. LMAT: 39.10 )
LMAT' s 10-Year Shiller P/E Range
Min: 34.05   Max: 162.5
Current: 39.1

34.05
162.5
Current Ratio 4.84
LMAT's Current Ratio is ranked higher than
87% of the 289 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.62 vs. LMAT: 4.84 )
LMAT' s 10-Year Current Ratio Range
Min: 2.12   Max: 8.11
Current: 4.84

2.12
8.11
Quick Ratio 3.17
LMAT's Quick Ratio is ranked higher than
84% of the 289 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.79 vs. LMAT: 3.17 )
LMAT' s 10-Year Quick Ratio Range
Min: 1.11   Max: 6.98
Current: 3.17

1.11
6.98
Days Inventory 245.01
LMAT's Days Inventory is ranked higher than
53% of the 309 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 123.27 vs. LMAT: 245.01 )
LMAT' s 10-Year Days Inventory Range
Min: 76.75   Max: 266.3
Current: 245.01

76.75
266.3
Days Sales Outstanding 55.46
LMAT's Days Sales Outstanding is ranked higher than
83% of the 309 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 69.40 vs. LMAT: 55.46 )
LMAT' s 10-Year Days Sales Outstanding Range
Min: 48.86   Max: 61.82
Current: 55.46

48.86
61.82

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 1.75
LMAT's Dividend Yield is ranked higher than
66% of the 151 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.31 vs. LMAT: 1.75 )
LMAT' s 10-Year Dividend Yield Range
Min: 0.28   Max: 1.98
Current: 1.75

0.28
1.98
Dividend Payout 0.61
LMAT's Dividend Payout is ranked higher than
77% of the 309 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.00 vs. LMAT: 0.61 )
LMAT' s 10-Year Dividend Payout Range
Min: 0.6   Max: 0.63
Current: 0.61

0.6
0.63
Dividend growth (3y) 20.50
LMAT's Dividend growth (3y) is ranked higher than
88% of the 121 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 10.00 vs. LMAT: 20.50 )
LMAT' s 10-Year Dividend growth (3y) Range
Min: 0   Max: 20.5
Current: 20.5

0
20.5
Yield on cost (5-Year) 1.70
LMAT's Yield on cost (5-Year) is ranked higher than
58% of the 154 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.57 vs. LMAT: 1.70 )
LMAT' s 10-Year Yield on cost (5-Year) Range
Min: 0.28   Max: 1.98
Current: 1.7

0.28
1.98
Share Buyback Rate -2.10
LMAT's Share Buyback Rate is ranked higher than
78% of the 232 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: -2.40 vs. LMAT: -2.10 )
LMAT' s 10-Year Share Buyback Rate Range
Min: 0.7   Max: -22.6
Current: -2.1

Valuation & Return

vs
industry
vs
history
Price/Net Cash 26.70
LMAT's Price/Net Cash is ranked higher than
89% of the 309 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.00 vs. LMAT: 26.70 )
LMAT' s 10-Year Price/Net Cash Range
Min: 2.85   Max: 160.2
Current: 26.7

2.85
160.2
Price/Net Current Asset Value 6.60
LMAT's Price/Net Current Asset Value is ranked higher than
91% of the 309 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.00 vs. LMAT: 6.60 )
LMAT' s 10-Year Price/Net Current Asset Value Range
Min: 1.27   Max: 4.5
Current: 6.6

1.27
4.5
Price/Tangible Book 3.30
LMAT's Price/Tangible Book is ranked higher than
81% of the 309 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.90 vs. LMAT: 3.30 )
LMAT' s 10-Year Price/Tangible Book Range
Min: 1.13   Max: 3.54
Current: 3.3

1.13
3.54
Price/DCF (Projected) 1.70
LMAT's Price/DCF (Projected) is ranked higher than
84% of the 309 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.56 vs. LMAT: 1.70 )
LMAT' s 10-Year Price/DCF (Projected) Range
Min: 1.55   Max: 2.5
Current: 1.7

1.55
2.5
Price/Median PS Value 1.10
LMAT's Price/Median PS Value is ranked higher than
77% of the 309 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.26 vs. LMAT: 1.10 )
LMAT' s 10-Year Price/Median PS Value Range
Min: 0.43   Max: 1.34
Current: 1.1

0.43
1.34
Price/Peter Lynch Fair Value 4.60
LMAT's Price/Peter Lynch Fair Value is ranked higher than
87% of the 309 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.00 vs. LMAT: 4.60 )
LMAT' s 10-Year Price/Peter Lynch Fair Value Range
Min: 4.3   Max: 4.3
Current: 4.6

Price/Graham Number 2.30
LMAT's Price/Graham Number is ranked higher than
87% of the 309 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 13.00 vs. LMAT: 2.30 )
LMAT' s 10-Year Price/Graham Number Range
Min: 1.48   Max: 2.47
Current: 2.3

1.48
2.47
Earnings Yield (Greenblatt) 5.10
LMAT's Earnings Yield (Greenblatt) is ranked higher than
84% of the 291 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.50 vs. LMAT: 5.10 )
LMAT' s 10-Year Earnings Yield (Greenblatt) Range
Min: 1.6   Max: 10.1
Current: 5.1

1.6
10.1
Forward Rate of Return (Yacktman) 10.04
LMAT's Forward Rate of Return (Yacktman) is ranked higher than
74% of the 170 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 10.05 vs. LMAT: 10.04 )
LMAT' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -2.3   Max: 26.5
Current: 10.04

-2.3
26.5

Business Description

Industry: Medical Instruments & Equipment » Medical Instruments & Supplies
Compare:WST, BAX, COV, TMO, COO » details
LeMaitre Vascular, Inc., was incorporated in Massachusetts on November 28, 1983, as Vascutech, Inc. On April 6, 2001, the Company changed its name to LeMaitre Vascular, Inc. The Company is a provider of medical devices and implants for the treatment of peripheral vascular disease. It develops, manufactures, and markets vascular devices to address the needs of vascular surgeons. Its diversified portfolio of peripheral vascular devices consists of brand name products that are used in arteries and veins outside of the heart and are well known to vascular surgeons, including the Expandable LeMaitre Valvulotome, the Pruitt F3 Carotid Shunt, VascuTape Radiopaque Tape and the XenoSure biologic patch. Its products are used by vascular surgeons who treat peripheral vascular disease through both open surgical methods and endovascular techniques. In contrast to interventional cardiologists and interventional radiologists, neither of whom are certified to perform open surgical procedures, vascular surgeons can perform both open surgical and minimally invasive endovascular procedures, and are therefore positioned to provide treatment options to patients. The principal product lines include the following: valvulotomes, balloon catheters, carotid shunts, biologic vascular patches, radiopaque marking tape, anastomotic clips, remote endarterectomy devices, laparoscopic cholecystectomy devices, vascular grafts, and powered phlebectomy. It has completed fourteen acquisitions of complementary products since 1998. The Company also sells non-vascular medical devices used in general surgery procedures, primarily laparoscopic cholecystectomy. Its leading general surgery product is the Reddick Cholangiogram Catheter, which is used to inject dye into the cystic duct during laparoscopic cholecystectomy. In this procedure, the gall bladder is dissected and removed through small punctures in the abdomen. It also offers two laparoscopic accessories used in laparoscopic gall bladder removal. Notable competitors of the Company include Applied Medical Resources Corporation, Baxter International, Inc., Cardiovascular Systems, Inc., C.R. Bard, Inc., Edwards Lifesciences Corporation, Getinge AB, Jotec GmbH, SAS Perouse Medical, Terumo Medical Corporation, Uresil, LLC, and W. L. Gore & Associates. It relies on a combination of patents, trademarks, trade secret laws, and confidentiality and invention assignment agreements to protect its intellectual property rights. The products are medical devices subject to extensive regulation by the FDA under the Federal Food, Drug, and Cosmetic Act (the FDCA).
» More Articles for LMAT

Headlines

Articles On GuruFocus.com
LeMaitre Vascular Inc. Reports Operating Results (10-Q) Nov 10 2010 
LeMaitre Vascular Inc. Reports Operating Results (10-Q) Aug 12 2010 
LeMaitre Vascular Inc. Reports Operating Results (10-Q) May 13 2010 
LeMaitre Vascular Inc. Reports Operating Results (10-Q) Nov 13 2009 
LeMaitre Vascular Inc. (LMAT) CEO George W Lemaitre buys 1,500 Shares Jun 05 2009 
LeMaitre Vascular Inc. (LMAT) CEO George W Lemaitre buys 1,250 Shares May 28 2009 
LeMaitre Vascular Inc. (LMAT) CEO George W Lemaitre buys 1,000 Shares May 18 2009 
LeMaitre Vascular Inc. Reports Operating Results (10-Q) May 14 2009 


More From Other Websites
NxStage Medical Opens New Dialysis Center in Maryland - Analyst Blog Apr 01 2015
Neogen Adds Reveal for Multi-Treenut to Food Allergen Tests - Analyst Blog Apr 01 2015
Healthways Completes Evaluation of Strategic Alternatives - Analyst Blog Apr 01 2015
Medtronic's CoreValve Wins Regulatory Approval in Japan - Analyst Blog Mar 31 2015
Akers Reports Narrower Loss in 2014, Revenues Surge Y/Y - Analyst Blog Mar 31 2015
Neogen Lags Q3 Earnings & Revenue Estimates, Stock Down - Analyst Blog Mar 27 2015
LEMAITRE VASCULAR INC Files SEC form 8-K, Changes in Registrant's Certifying Accountant, Financial... Mar 27 2015
Veeva (VEEV) OpenKey: A Key to Customer Data Referencing - Analyst Blog Mar 25 2015
LEMAITRE VASCULAR INC Financials Mar 25 2015
Why Eleven Biotherapeutics (EBIO) Could Be Positioned for a Slump - Tale of the Tape Mar 25 2015
NYSE Notice for Hanger for Non Compliance with 10-K Norms - Analyst Blog Mar 24 2015
Abaxis' (ABAX) Decision to Divest AVRL: A Strategic Fit? - Analyst Blog Mar 24 2015
LeMaitre Vascular a Strong Buy on Impressive Q4 - Analyst Blog Mar 23 2015
LeMaitre Vascular to Attend the Morgan Stanley Healthcare Corporate Access Day on Wednesday, April... Mar 20 2015
LeMaitre Vascular to Attend the Morgan Stanley Healthcare Corporate Access Day on Wednesday, April... Mar 20 2015
Medtronic Gains on Positive 2-Year CoreValve Trial Data - Analyst Blog Mar 20 2015
Mettler-Toledo Scales a 52-Week High on Bullish Trends - Analyst Blog Mar 20 2015
Medtronic Up on Positive Preclinical Drug-Filled Stent Results - Analyst Blog Mar 19 2015
Boston Scientific's Heart Device Wins FDA Nod, CE Mark - Analyst Blog Mar 19 2015
Zacks Rank #1 Additions for Thursday - Tale of the Tape Mar 19 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK